Natera at Canaccord Conference: Growth and Innovation in Focus

Natera Inc. presented a strong growth outlook at the Canaccord Genuity conference, reporting record Signatera clinical unit growth to 180,000 units and significant gross margin improvement to 63%, targeting 70%. The company anticipates a $250M-$300M incremental revenue opportunity from expanded Medicare reimbursement for new indications and plans to launch an FDA-approved colon cancer screening test by 2028, signaling aggressive market expansion and a focus on sustainable cash flow generation amidst competitive pressures.

Analysis

Natera (NTRA) presented a robust operational and financial update, highlighting significant momentum in its core oncology business. The Signatera test achieved record sequential growth, adding 20,000 clinical units in Q2 to reach approximately 180,000, driven by an exceptional increase in new patient starts which totaled 6,000. This performance is underpinned by a strong wave of positive clinical trial data, enhancing physician adoption. Financially, the company has demonstrated significant operating leverage, with gross margins expanding from 39% to 63% over the last two years and a long-term target of 70%. Management reaffirmed its path to sustainable cash flow generation for the full year, noting that current OpEx growth is a strategic investment in future opportunities for 2027 and beyond, not required for near-term revenue. Key future catalysts include a $250-$300 million incremental revenue opportunity from pursuing Medicare reimbursement for new indications over the next 12-18 months and the planned launch of an FDA-approved colon cancer screening test by 2028. While acknowledging rising competition, Natera's strategy is to maintain its lead through continuous product innovation, superior clinical data, and leveraging its established commercial infrastructure.

Key Decisions for Investors

• Investors should monitor the continued quarter-over-quarter growth in Signatera units and new patient starts as the primary indicator of sustained market leadership and execution against increasing competition.
• The identified $250-$300 million revenue opportunity from expanded Medicare reimbursement represents a critical mid-term catalyst; tracking progress on these submissions will be crucial for modeling future average selling price (ASP) and revenue growth.
• Consider the current operating expense growth as a long-term investment in the post-2026 pipeline, while assessing the company's progress toward its 70% gross margin target and its ability to maintain cash flow positivity to self-fund these ambitions.